PT35 Cost-Effectiveness Analysis of Nivolumab Versus Docetaxel for the Treatment of Advanced Nonsquamous NSCLC Including PD-L1 Testing in the United States
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.2448
https://www.valueinhealthjournal.com/article/S1098-3015(24)02662-7/fulltext
Title :
PT35 Cost-Effectiveness Analysis of Nivolumab Versus Docetaxel for the Treatment of Advanced Nonsquamous NSCLC Including PD-L1 Testing in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)02662-7&doi=10.1016/j.jval.2024.03.2448
First page :
Section Title :
Open access? :
No
Section Order :
11286